SANOFI_Presentation_EN

CORPORATE PRESENTATION 2011 1

Corporate Presentation

SANOFIA global healthcare leader, focused on patients’ needs

A global healthcare leader,focused on patients’ needs

2

world’s largest pharmaceutical groups

1employees in110,000€30.4

3.7% (1) growth in net sales for 2010

billion

(1) a reported basis

countries100

CORPORATE PRESENTATION 2011

of the

Source : 20F Form 2010, employees estimation march 2011, annual review 2010

1973 to 2008 2009 to 2011

300 mergers and acquisitions

Diversified Healthcare Leader

10 110,000Employees

Health, Beauty, Nutrition

Evolution

3CORPORATE PRESENTATION 2011

Acquired companies including Genzyme

+61in-licensing agreements

+2 joint ventures

Invested a total of ~ €23bn in external growth

23

Source: employees estimation march 2011, IR presentation September 6, 2011

History of Sanofi

4

Sanofi-Synthélabo

1999

Sanofi1973

Synthélabo1970

Sanofi-aventis

2004

Aventis1999

HoechstMarion Roussel

1997

Rhône-Poulenc Rorer

1990

Chinoin1919

Sterling

1901

Midy1718

Hoechst1920

Marion1950

Institut Pasteur

1887

Rorer1910

Connaught1922

Delalande1924

Delagrange1931

BMP Sunstone, Medley,Merial, Nepentes, Zentiva, Kendricks,

Oenobiol, Chattem, Acambis, Symbion, Shantha Biotechnics

2008-2010

Roussel1911

Genzyme2011


Our commitment

5

Sanofi is more thana pharmaceutical laboratory;

We act with our partners to protect health, enhance life and respondto the potential healthcare needs of the 7 billion people around the world

we are a diversified healthcare company


Our ambition

6

We demonstrate leadership bothin business achievements and in the communitiesin which we operate

We are a global healthcare leader, focused on patients’ needs

We wish to be known for our abilityto transformscientific innovations into therapeutic solutions for patients


Our global presence

7

(1) US + Canada + Porto Rico(2) Western Europe + Eastern Europe + Turkey(3) Australia + New Zealand

Africa, Middle East

€846 M€789 M

Employees

Sales Africa

Europe (2)

€11,609 MEmployees

Sales

North America (1)

€9,484 M+15,000

Sales

Employees

South America

€2,735 M9,000

Sales

Employees

Japan

€2,225 MEmployees

Sales

Asia, Pacific (3)

€1,983 M€713 M

Sales Asia

Employees+4,500

55,000 +3,000

+15,000

SalesMiddle East

SalesPacific


Source: Solid results in 2010, press release Febuary 9th 2011

Our strategy

8

INCREASEINNOVATIONIN R&D

SEIZEEXTERNAL GROWTH OPPORTUNITIES

ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES

1 2 3


Accelerate innovation for patients

9

1. INCREASE INNOVATION IN R&D

Sanofi R&DA new R&D model to improve health worldwide and bring therapeutic solutions to patients:

• Simplification

• Openness

• Partnerships

• Biotechnologies

PrioritiesDiabetes

Fibrosis and tissue repair

Immuno-inflammation

Infectious diseases

Rare diseases

Oncology

Ophthalmology

Aging

R&D Portfolio Q2 results 2011

molecules and vaccines

65

2012 - 201519 potential new launches*


Source: IR presentation September 6, 2011

Develop innovative health solutions

10

1. INCREASE INNOVATION IN R&D

Dengue vaccine

Note : LemtradaTM (alemtuzumab), AubagioTM (teriflunomide) and Lyxumia® (lixisenatide) are brand names for projects currently in development for which all necessary regulatory authorizations have not been attained. (1) Licensed by Zealand Pharma A/S, expected regulatory submission in EU Q4 2011 and US Q4 2012(2) expected regulatory submission in MS in US and EU Q1 2012(3) filed in the US in Q3 2011 and expected regulatory submission in EU Q1 2012)

(1)


(2014)

Oncology Diabetes Vaccines

Multiple sclerosis Biosurgey renal


(2)

(3)

Strengthen our activities through external growth

11

2. SEIZE EXTERNAL GROWTH OPPORTUNITIES

Generics

Human vaccines

Consumerhealthcare

Diabetes

Rare diseases

Innovativeproducts

Animalhealth


REGULUS

acquisitions and partnerships

In 2009

acquisitions and partnerships

In 2010

33

37

Source : annual review 2009 and 2010

Growth platforms: 57% of sales in 2010 (1)

12

3. ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNI TIES

Emerging markets

Human vaccines

Consumer healthcare

Diabetes solutions

Innovative products

Animal health



(1) Including sales of merial

Emerging markets (1): a new world vision

13

Brazil

China

Russia

+51.4 % (2)

+23.6 % (2)

+19.9 % (2)

Sales Split (%):

Results

#1

#3

#2

(1) The World less the United States, Canada, Western Europe, Japan, Australia and New Zealand.Organic growth in emerging markets: + 13.2% in 2010.

(2) At constant exchange rates.(3) RoW: Japan, Australia, New Zealand, Canada


+16.3 % (2)


30.4 %

12.2 %

28.5 %

28.9 %U.S.

RoW (3)

EmergingMarkets

WesternEurope

local production sites support market access

38

employees40,000Nearly

Source : annual review 2010, presentation of Q2 2011 Results, IR presentation September 6, 2011

Human vaccines: Sanofi Pasteur, a world leader

14

Dengue vaccine

Clostridium difficile vaccine

(1) Growth at constant exchange rates


Leadership position in pediatrics , flu , meningitis, travel & endemics

Broad Product OfferingSales Split 2011 e

Flu Polio / Pertussis /Hib

Boosters

Other 6%

12%

11%

27%

13%

31%

Meningitis /PneumoTravel /

Endemics

Today

Tomorrow €3.8 bn+4.8% (1) consolidated sales in 2010

doses of seasonal influenza vaccine distributed worldwide

198,000,000In 2010

12.5 %

Vaccines for

20infectious diseases


of Sanofi sales

Source : annual rewiew 2010, presentation General meeting 2011 May 6, 2011, IR presentation September 6, 2011

Consumer healthcare: diversification and strong growth

15

Keys legacy brands

In March 2011Launchof Allegra®

over the counterin the US

€2,2

(1) Includes Chattem sales since 10 February 2010+6.9% in 2010 on a constant structure basis ant at constant exchange rates


bn2010 Sales: +45.7 % (1)

Sanofi has becomea global player (2)

#1in Latin America, in Australia

#3in Russia, in Central & Eastern Europe

Scaling upin China and AsiaAmong top 10 in U.S (3)


(2) Nicolas Hall, OTC Yearbook, 2011, DBG 2011 (2011 Sales)(3) Including Allegra® OTC sales in 2011, internal estimates

Source : annual rewiew 2010, IR presentation September 6, 2011

Diabetes solutions

16

Lantus®

Amaryl®

Apidra®

BGStar® and iBGStar®

BGStar® and iBGStar®

Integrate BGM and Lantus® dosing device Lyxumia®

(lixisenatide)Type 2 diabetes

Lantus ® in 2010

120,000,000Lantus® and SoloSTAR®

pens sold

insulin brand name worldwide

+9.2% (1)

14.1% of Sanofi sales #1

#1

€3.5 bn

diabetes treatmentwith sales of

Today

Tomorrow

€4,3 bn



(1) Growth at constant exchange ratesSource : annual rewiew 2010, presentation General meeting 2011 May 6, 2011, IR presentation September 6, 2011

Innovative products: bringing new hope

17

Kynamro ™ (mipomersen)hoFH(1) and Severe heFH(2)

Visamerin ®

Mulsevo ® (semuloparin)VTE(3) prevention inchemo-treated patients

Aubagio ™ (Teriflunomide) RMS(4)

Zaltrap ™ (Aflibercept) 2L-mCRC(5)

Lyxumia ® (lixisenatide) Type 2 diabetes

Lemtrada ™ (alemtuzumab) RMS

(1) Homozygous Familial Hypercholesterolemia(2) Heterozygous Familial Hypercholesterolemia(3) Venous Thrombo Embolism(4) Relapsing forms of Multiple Sceloris(5) Metastatic Colorectal Cancer



Source : IR presentation September 6, 2011

Animal health: Merial

18

More than

€2.6 bn

employees worldwide

150 countries

production sites

16

in sales in 2010, +2.6% (1)

5,700

With its range of vaccines and products to treat parasites, infection, inflammation and ulcers, Merial improves the health, well-being and performance of a large variety of animals.

(1) Growth at constant exchange rates

Present in more than



Source : annual rewiew 2010

Genzyme, a Sanofi company

19CORPORATE PRESENTATION 2011


TodayGlobal leader in rare genetic diseases

Established, long-term partnerships

- KOLs,

- Patient groups,

- Health authorities

Technical expertise across broad range of technology platforms

Tomorrow

Personalized Genetic Health

Multiple Sclerosis (1)

(1) LemtradaTM (alemtuzumab), AubagioTM (teriflunomide) are brand names for projects currently in development for which all necessary regulatory authorizations have not been attained.

70

40sites in more than

in sales in 2010

countries

$1,571mpersonalized Genetic Health

Source : annual rewiew 2010, IR presentation September 6, 2011

Corporate social responsibility

20

We are a healthcare company with deep moral commitments

Acting ethically and responsibly is part of our DNA

Giving aid, both in emergencies and on a daily basis, means going beyond our immediate obligationsto protect and serveas many human beingsas possible.


Ensuring access to healthcare

21

CORPORATE SOCIAL RESPONSIBILITY

To ensure that the human right to health becomesa reality, Sanofi develops programs to improve access to medicinesfor people in developing countries

7 disease areasfor Accessto MedicinesMalaria Tuberculosis Sleeping sicknessLeishmaniasisEpilepsy Mental health Vaccines

Approach Information and education,

Medicines adapted to patients needs,

Tiered pricing policy

R&D program for therapeutic innovation


22


Respond

Support

Encourage

Donations in 2010:

boxes of medicinesand

vaccine doses to treat underprivileged people in

43 countriesemployee involvement

development aid

to humanitarian emergencies 974,457

509,218



23


HAITI

Bringing access to healthcare to the population after the earthquake

FRANCE

Improving medical care for the homeless

ALGERIA

Diagnosing and socially rehabilitating children with mental difficulties

BRESIL

Fighting leishmaniasis

BURUNDI

Training healthcare professionals.

NEPAL

Fighting infant and maternal mortality

INDIA

Combining access to healthcare and mutual health support

PHILIPPINES

Caring for street childrenTOGO

Fighting Buruli ulcer

TANZANIA

Fighting childhood cancer

Our dedication to healthcare for all: a few examples from around the world

PÉROU

Enhancing access to healthcare in slums

PERU


Source : annual rewiew 2010,

Embracing environmental responsibility

24


Safeguarding the environment is one of Sanofi’s responsibilities as a global healthcare partner. The connection between environmental hazards and impact on health has been clearly established.

Because we are focused on patients’ needs, reducing environmental risk is a natural part of our CSR practices

Carbon footprint and energy consumption

One of Sanofi’s priority to reduce its environmental impact is to control our carbon footprintand reduce our energy consumption.

Since 2005, for every unit produced, the Group has decreased direct CO2 emissions by 8 % and indirect emissions by 17 %.



Recommendation

25PRÉSENTATION INSTITUTIONNELLE 2011

This corporate presentation is available for all em ployees in the Sanofi Group. It may be used internally or externally for present ations of the Group, either in whole or in part, as needed.

The information is taken from Information meetings, annual results 2010 and from press releases.

Further information is available on www.sanofi.com

Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Photography credits : Urbanhearts/Fotolia - Gil Corre - Krzysztof Dydynski/lonely Planet Images/Getty Images - Imagesource V/Fotolia - Gil Corre - Eric Larrayadieu/Interlinks Image - Merial - Julien Chraibi - Gil Corre - Gil Corre (Haïti, Brésil, France, Tanzanie) -samusocial International (Pérou) - Santé Sud (Algérie) - Jean-Jacques Bernard (Togo) - Chirurgie solidaire (Burundi) - InterAide (Inde) - Stéphane Lehr (Népal) - Virlanie (Philippines) – Getty Images/MIXA

26

Further informations:www.sanofi.com

SANOFI

Headquarters 174, avenue de France 75013 Paris, FranceTel. +33 (0)1 53 77 40 00


Documents

SANOFI_Presentation_EN